4-(8-((3,4-二甲基苯基)氨基磺酰基)-3A,4,5,9B-四氢-3H-环戊二烯并[C]喹啉-4-基)苯甲酸 | 1005264-47-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-(8-((3,4-二甲基苯基)氨基磺酰基)-3A,4,5,9B-四氢-3H-环戊二烯并[C]喹啉-4-基)苯甲酸
• 英文名称: 4-[8-[(3,4-dimethylphenyl)sulfamoyl]-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-4-yl]benzoic acid
• CAS: 1005264-47-0
• 化学式: C₂₇H₂₆N₂O₄S
• 分子量: 474.6
• InChiKey: XCBONKHCCRJMNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• METHODS OF TREATING CANCER
  申请人：Kartos Therapeutics, Inc.

  公开号：EP3787625A1

  公开（公告）日：2021-03-10
• METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS
  申请人：Kartos Therapeutics, Inc.

  公开号：EP3801476A2

  公开（公告）日：2021-04-14
• METHODS AND COMPOSITIONS OF TREATING AN OPHTHALMIC CONDITION
  申请人：Kartos Therapeutics

  公开号：EP3927344A1

  公开（公告）日：2021-12-29
• Methods of Treating Cancer
  申请人：Kartos Therapeutics, Inc.

  公开号：US20210186946A1

  公开（公告）日：2021-06-24

  Therapeutic methods and pharmaceutical compositions for treating cancer including a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis in a human subject are described. In certain embodiments, the invention includes therapeutic methods of treating a MPN using a MDM2 inhibitor of Formula (I) or Formula (II).
• Methods of Treating Myeloproliferative Neoplasms
  申请人：Kartos Therapeutics, Inc.

  公开号：US20220054472A1

  公开（公告）日：2022-02-24

  Therapeutic methods and pharmaceutical compositions for treating a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis, are described. In certain embodiments, the invention includes therapeutic methods of treating a MPN using a combination of a compound of Formula (I) or Formula (II) with a therapeutic agent selected from the group consisting of a JAK inhibitor, an IDH inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a PD-L2 inhibitor, an interferon, a PI3K inhibitor, an AKT inhibitor, an mTOR inhibitor, a nucleoside analog, and combinations thereof.